<?xml version='1.0' encoding='utf-8'?>
<document id="20395869"><sentence text="Drug-drug interactions between raltegravir and pravastatin in healthy volunteers."><entity charOffset="47-58" id="DDI-PubMed.20395869.s1.e0" text="pravastatin" /></sentence><sentence text="To evaluate the potential drug-drug interaction between raltegravir and pravastatin"><entity charOffset="72-83" id="DDI-PubMed.20395869.s2.e0" text="pravastatin" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, 3-period, cross-over, single-centre trial in 24 healthy volunteers" /><sentence text=" Subjects received the following treatments: pravastatin 40 mg every day for 4 days, raltegravir 400 mg twice a day for 4 days, and pravastatin 40 mg every day + raltegravir 400 mg twice a day for 4 days"><entity charOffset="45-56" id="DDI-PubMed.20395869.s5.e0" text="pravastatin" /><entity charOffset="132-143" id="DDI-PubMed.20395869.s5.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.20395869.s5.e0" e2="DDI-PubMed.20395869.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20395869.s5.e0" e2="DDI-PubMed.20395869.s5.e1" /></sentence><sentence text=" The treatments were separated by washout periods of 10 days" /><sentence text=" On day 4 of each treatment period, blood samples for pharmacokinetics were collected throughout a 24-hour period" /><sentence text="" /><sentence text="Geometric mean ratios (90% confidence interval) for pravastatin + raltegravir versus pravastatin alone were 0"><entity charOffset="85-96" id="DDI-PubMed.20395869.s9.e0" text="pravastatin" /></sentence><sentence text="96 (0" /><sentence text="83 to 1" /><sentence text="11) for AUC0-24 and 1" /><sentence text="04 (0" /><sentence text="85 to 1" /><sentence text="26) for Cmax" /><sentence text=" The mean low-density lipoprotein cholesterol decrease after 4 days of pravastatin was 0"><entity charOffset="34-45" id="DDI-PubMed.20395869.s16.e0" text="cholesterol" /><entity charOffset="71-82" id="DDI-PubMed.20395869.s16.e1" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.20395869.s16.e0" e2="DDI-PubMed.20395869.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20395869.s16.e0" e2="DDI-PubMed.20395869.s16.e1" /></sentence><sentence text="42 mmol/L both in the presence and the absence of raltegravir"><entity charOffset="50-61" id="DDI-PubMed.20395869.s17.e0" text="raltegravir" /></sentence><sentence text=" The geometric mean ratio (90% confidence interval) AUC0-12, Cmax, and C12 for raltegravir + pravastatin versus raltegravir alone were 1" /><sentence text="13 (0" /><sentence text="77 to 1" /><sentence text="65), 1" /><sentence text="31 (0" /><sentence text="81 to 2" /><sentence text="13), and 0" /><sentence text="59 (0" /><sentence text="39 to 0" /><sentence text="88), respectively" /><sentence text="" /><sentence text="Raltegravir did not influence the pharmacokinetics or the short-term lipid-lowering effects of pravastatin, whereas pravastatin increased the Cmax but decreased the C12 of raltegravir"><entity charOffset="95-106" id="DDI-PubMed.20395869.s29.e0" text="pravastatin" /><entity charOffset="116-127" id="DDI-PubMed.20395869.s29.e1" text="pravastatin" /><entity charOffset="172-183" id="DDI-PubMed.20395869.s29.e2" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.20395869.s29.e0" e2="DDI-PubMed.20395869.s29.e0" /><pair ddi="false" e1="DDI-PubMed.20395869.s29.e0" e2="DDI-PubMed.20395869.s29.e1" /><pair ddi="false" e1="DDI-PubMed.20395869.s29.e0" e2="DDI-PubMed.20395869.s29.e2" /><pair ddi="false" e1="DDI-PubMed.20395869.s29.e1" e2="DDI-PubMed.20395869.s29.e1" /><pair ddi="false" e1="DDI-PubMed.20395869.s29.e1" e2="DDI-PubMed.20395869.s29.e2" /></sentence><sentence text=" The effects of pravastatin on raltegravir pharmacokinetics are not likely to be clinically relevant"><entity charOffset="16-27" id="DDI-PubMed.20395869.s30.e0" text="pravastatin" /><entity charOffset="31-42" id="DDI-PubMed.20395869.s30.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.20395869.s30.e0" e2="DDI-PubMed.20395869.s30.e0" /><pair ddi="false" e1="DDI-PubMed.20395869.s30.e0" e2="DDI-PubMed.20395869.s30.e1" /></sentence><sentence text="" /></document>